RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma

Diagnostic Pathology

Volumn 4, Issue 1, 2009, Pages

  Li, Mao ^a   Xu, Jianjiang ^a   Chen, Xueli ^a   Sun, Xinghuai ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74849104278     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-4-46     Document Type: Article

References (41)

1. Primary open-angle glaucoma. RN Weinreb PT Khaw, Lancet 2004 363 1711 1720 10.1016/S0140-6736(04)16257-0 15158634
2. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. B Rahmani JM Tielsch J Katz J Gottsch H Quigley J Javitt A Sommer, Ophthalmology 1996 103 1721 1726 8942862
3. Models of open-angle glaucoma prevalence and incidence in the United States. HA Quigley S Vitale, Invest Ophthalmol Vis Sci 1997 38 83 91 9008633
4. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. AR Rudnicka S Mt-Isa CG Owen DG Cook D Ashby, Invest Ophthalmol Vis Sci 2006 47 4254 4261 10.1167/iovs.06-0299 17003413
5. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Y Liu D Vollrath, Hum Mol Genet 2004 13 1193 1204 10.1093/hmg/ddh128 15069026
6. American Academy of Ophthalmology PPPC, Glaucoma Panel, Preferred practice pattern: primary open-angle glaucoma San Francisco, Calif: American Academy of Ophthalmology 2000
7. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. MA Kass DK Heuer EJ Higginbotham CA Johnson JL Keltner JP Miller RK Parrish MR Wilson MO Gordon, Arch Ophthalmol 2002 120 701 713 12049574
8. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. A Heijl MC Leske B Bengtsson L Hyman M Hussein, Arch Ophthalmol 2002 120 1268 1279 12365904
9. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. PR Lichter DC Musch BW Gillespie KE Guire NK Janz PA Wren RP Mills, Ophthalmology 2001 108 1943 1953 10.1016/S0161-6420(01)00873-9 11713061
10. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998 105 1146 1164 10.1016/S0161-6420(98)97013-0 9663215
11. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. JH Fingert E Héon JM Liebmann T Yamamoto JE Craig J Rait K Kawase ST Hoh YM Buys J Dickinson RR Hockey D Williams-Lyn G Trope Y Kitazawa R Ritch DA Mackey WL Alward VC Sheffield EM Stone, Hum Mol Genet 1999 8 899 905 10.1093/hmg/8.5.899 10196380
12. Gene therapy for glaucoma: treating a multifaceted, chronic disease. T Borras CR Brandt R Nickells R Ritch, Invest Ophthalmol Vis Sci 2002 43 2513 2518 12147578
13. Localization of myocilin/trabecular meshwork - inducible glucocorticoid response protein in the human eye. A Karali P Russell FH Stefani ER Tamm, Invest Ophthalmol Vis Sci 2000 41 729 740 10711688
14. Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization. RE Swiderski JL Ross JH Fingert AF Clark WL Alward EM Stone VC Sheffield, Invest Ophthalmol Vis Sci 2000 41 3420 3428 11006234
15. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. MF Adam A Belmouden P Binisti AP Brézin F Valtot A Béchetoille JC Dascotte B Copin L Gomez A Chaventré JF Bach HJ Garchon, Hum Mol Genet 1997 6 2091 2097 10.1093/hmg/6.12.2091 9328473
16. Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function. BS Kim OV Savinova MV Reedy J Martin Y Lun L Gan RS Smith SI Tomarev SW John RL Johnson, Mol Cell Biol 2001 21 7707 7713 10.1128/MCB.21.22.7707-7713.2001 11604506
17. TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma. CP Pang YF Leung B Fan L Baum WC Tong WS Lee JK Chua DS Fan Y Liu DS Lam, Invest Ophthalmol Vis Sci 2002 43 3231 3235 12356829
18. Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. JL Wiggs D Vollrath, Arch Ophthalmol 2001 119 1674 1678 11709019
19. Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma. DB Gould L Miceli-Libby OV Savinova M Torrado SI Tomarev RS Smith SW John, Mol Cell Biol 2004 24 9019 9025 10.1128/MCB.24.20.9019-9025.2004 15456875
20. Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice. M Zillig A Wurm FJ Grehn P Russell ER Tamm, Invest Ophthalmol Vis Sci 2005 46 223 234 10.1167/iovs.04-0988 15623777
21. Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain. M Caballero LL Rowlette T Borras, Biochim Biophys Acta 2000 1502 447 460 11068187
22. Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma. M Caballero T Borras, Biochem Biophys Res Commun 2001 282 662 670 10.1006/bbrc.2001.4624 11401512
23. Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities. S Sohn W Hur MK Joe JH Kim ZW Lee KS Ha C Kee, Invest Ophthalmol Vis Sci 2002 43 3680 3685 12454036
24. Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. MK Joe S Sohn W Hur Y Moon YR Choi C Kee, Biochem Biophys Res Commun 2003 312 592 600 10.1016/j.bbrc.2003.10. 162 14680806
25. Intracellular sequestration of hetero-oligomers formed by wild-type and glaucoma-causing myocilin mutants. S Gobeil MA Rodrigue S Moisan TD Nguyen JR Polansky J Morissette V Raymond, Invest Ophthalmol Vis Sci 2004 45 3560 3567 10.1167/iovs.04-0300 15452063
26. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. N Jacobson M Andrews AR Shepard D Nishimura C Searby JH Fingert G Hageman R Mullins BL Davidson YH Kwon WL Alward EM Stone AF Clark VC Sheffield, Hum Mol Genet 2001 10 117 125 10.1093/hmg/10.2.117 11152659
27. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion. S Gobeil L Letartre V Raymond, Exp Eye Res 2006 82 1017 1029 10.1016/j.exer.2005.11.002 16466712
28. Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma. GH Yam K Gaplovska-Kysela C Zuber J Roth, Am J Pathol 2007 170 100 109 10.2353/ajpath.2007.060806 17200186
29. ER stress and the unfolded protein response. M Schroder RJ Kaufman, Mutat Res 2005 569 29 63 15603751
30. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. J Alvarado C Murphy R Juster, Ophthalmology 1984 91 564 579 6462622
31. Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals. JA Alvarado AJ Yun CG Murphy, Arch Ophthalmol 1986 104 1517 1528 3767685
32. Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. E Lutjen-Drecoll T Shimizu M Rohrbach JW Rohen, Exp Eye Res 1986 42 443 455 10.1016/0014-4835(86)90004-7 3720863 (Pubitemid 16121084)
33. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). JW Rohen E Lutjen-Drecoll C Flugel M Meyer I Grierson, Exp Eye Res 1993 56 683 692 10.1006/exer.1993.1085 8595810
34. The RNAi revolution. CD Novina PA Sharp, Nature 2004 430 161 164 10.1038/430161a 15241403
35. Molecular biology. Argonaute journeys into the heart of RISC. EJ Sontheimer RW Carthew, Science 2004 305 1409 1410 10.1126/science.1103076 15353786
36. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. NJ Caplen, Gene Ther 2004 11 1241 1248 10.1038/sj.gt.3302324 15292914
37. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. SM Elbashir J Harborth W Lendeckel A Yalcin K Weber T Tuschl, Nature 2001 411 494 498 10.1038/35078107 11373684
38. Allele-specific silencing of dominant disease genes. VM Miller H Xia GL Marrs CM Gouvion G Lee BL Davidson HL Paulson, Proc Natl Acad Sci USA 2003 100 7195 7200 10.1073/pnas.1231012100 12782788
39. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. AS Kiang A Palfi M Ader PF Kenna S Millington-Ward G Clark A Kennan M O'reilly LC Tam A Aherne N McNally P Humphries GJ Farrar, Mol Ther 2005 12 555 561 10.1016/j.ymthe.2005.03.028 15967729
40. Myocilin glaucoma. JH Fingert EM Stone VC Sheffield WL Alward, Surv Ophthalmol 2002 47 547 561 10.1016/S0039-6257(02)00353-3 12504739
41. Silencing gene therapy for mutant membrane, secretory, and lipid proteins in retinitis pigmentosa (RP). T Shinohara ML Mulhern CJ Madson, Med Hypotheses 2008 70 378 380 10.1016/j.mehy.2007.04.041 17590524